Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 5 Next >
News headline image
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Provides Update on Clinical and Financial Status
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports H1 2025 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Up To $15.0 Million Public Offering
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.